| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss for the period | -1,173,346 | -1,057,431 |
| Loss on liability settlement | -801,193 | -801,193 |
| Accounts payable and accrued expenses | 1,873 | 1,630 |
| Accrued board of directors compensation | 316,051 | 211,500 |
| Net cash flows used in operating activities | -54,229 | -43,108 |
| Proceeds from related parties | 54,151 | 43,151 |
| Capital contributions | - | 0 |
| Net cash flows provided by financing activities | 54,151 | 43,151 |
| Cash flows from investing activities | - | 0 |
| Net change in cash | -78 | 43 |
| Cash and cash equivalents at beginning of period | 862 | - |
| Cash and cash equivalents at end of period | 784 | - |
BIOFORCE NANOSCIENCES HOLDINGS, INC. (BFNH)
BIOFORCE NANOSCIENCES HOLDINGS, INC. (BFNH)